|
1
|
Al-Sohaily S, Biankin A, Leong R,
Kohonen-Corish M and Warusavitarne J: Molecular pathways in
colorectal cancer. J Gastroenterol Hepatol. 27:1423–1431. 2012.
|
|
2
|
Markowitz SD and Bertagnolli MM: Molecular
origins of cancer: Molecular basis of colorectal cancer. N Engl J
Med. 361:2449–2460. 2009.
|
|
3
|
Kondo Y and Issa JP: Epigenetic changes in
colorectal cancer. Cancer Metastasis Rev. 23:29–39. 2004.
|
|
4
|
Naghibalhossaini F, Zamani M, Mokarram P,
Khalili I, Rasti M and Mostafavi-Pour Z: Epigenetic and genetic
analysis of WNT signaling pathway in sporadic colorectal cancer
patients from Iran. Mol Biol Rep. 39:6171–6178. 2012.
|
|
5
|
Mammano E, Belluco C, Bonafé M, Olivieri
F, Mugianesi E, Barbi C, Mishto M, Cosci M, Franceschi C, Lise M
and Nitti D: Association of p53 polymorphisms and colorectal
cancer: modulation of risk and progression. Eur J Surg Oncol.
35:415–419. 2009.
|
|
6
|
Theodoropoulos G, Papaconstantinou I,
Felekouras E, Niketeas N, Karakitsos P, Panoussopoulos D, Lazaris
ACh, Patsouris E, Bramis J and Gazouli M: Relation between common
polymorphisms in genes related to inflammatory response and
colorectal cancer. World J Gastroenterol. 12:5037–5043. 2006.
|
|
7
|
Egeblad M and Werb Z: New functions for
the matrix metalloproteinases in cancer progression. Nat Rev
Cancer. 2:161–174. 2002.
|
|
8
|
Van Nguyen S, Skarstedt M, Löfgren S, Zar
N, Andersson RE, Lindh M, Matussek A and Dimberg J: Gene
polymorphism of matrix metalloproteinase-12 and -13 and association
with colorectal cancer in Swedish patients. Anticancer Res.
33:3247–3250. 2013.
|
|
9
|
Fang JY and Richardson BC: The MAPK
signaling pathways and colorectal cancer. Lancet Oncol. 6:322–327.
2005.
|
|
10
|
Dhillon AS, Hagan S, Rath O and Kolch W:
MAP kinase signaling pathways in cancer. Oncogene. 26:3279–3290.
2007.
|
|
11
|
Zarubin T and Han J: Activation and
signaling of the p38 MAP kinase pathway. Cell Res. 15:11–18.
2005.
|
|
12
|
Pailas S, Boissière F, Bibeau F, Denouel
A, Mollevi C, Causse A, Denis V, Vezzio-Vié N, Marzi L, Cortijo C,
et al: Targeting the p38 MAPK pathway inhibits irinotecan
resistance in colon adenocarcinoma. Cancer Res. 71:1041–1049.
2011.
|
|
13
|
Chen L, Mayer JA, Krisko TI, Speers CW,
Wang T, Hilsenbeck SG and Brown PH: Inhibition of the p38 kinase
suppresses the proliferation of human ER-negative breast cancer
cells. Cancer Res. 69:8853–8861. 2009.
|
|
14
|
Huang Q, Chen D, Song S, Fu X, Wei Y, Lu
J, Wang L and Wang J: A genetic variation of the p38β promoter
region is correlated with an increased risk of sporadic colorectal
cancer. Oncol Lett. 6:3–8. 2013.
|
|
15
|
Wu JS: Rectal cancer staging. Clin Colon
Rectal Surg. 20:148–157. 2007.
|
|
16
|
del Barco Barrantes I and Nebreda AR:
Roles of p38 MAPKs in invasion and metastasis. Biochem Soc Trans.
40:79–84. 2012.
|
|
17
|
Jormsjö S, Ye S, Moritz J, Walter DH,
Dimmeler S, Zeiher AM, Henney A, Hamsten A and Eriksson P:
Allele-specific regulation of matrix metalloproteinase-12 gene
activity is associated with coronary artery luminal dimensions in
diabetic patients with manifest coronary artery disease. Circ Res.
86:998–1003. 2000.
|
|
18
|
Benbow U and Brinckerhoff CE: The AP-1
site and MMP gene regulation: what is all the fuss about? Matrix
Biol. 15:519–526. 1997.
|
|
19
|
Simon C, Simon M, Vucelic G, Hicks MJ,
Plinkert PK, Koitschev A and Zenner HP: The p38 SAPK pathway
regulates the expression of the MMP-9 collagenase via
AP-1-dependent promoter activation. Exp Cell Res. 271:344–345.
2001.
|
|
20
|
Ashida R, Tominaga K, Sasaki E, Watanabe
T, Fujiwana Y, Oshitani N, Higuchi K, Mitsuyama S, Iwao H and
Arakawa T: AP-1 and colorectal cancer. Inflammopharmacology.
13:113–125. 2005.
|
